Invivyd (IVVD) Expected to Announce Earnings on Thursday

Invivyd (NASDAQ:IVVD) is expected to release its Q4 2025 results before the market opens on Thursday, March 5th. Analysts expect Invivyd to post earnings of ($0.06) per share and revenue of $15.5150 million for the quarter. Interested persons may visit the the company’s upcoming Q4 2025 earning results page for the latest details on the call scheduled for Thursday, March 5, 2026 at 8:30 AM ET.

Invivyd Trading Down 5.8%

IVVD stock opened at $1.62 on Wednesday. Invivyd has a 1-year low of $0.46 and a 1-year high of $3.07. The firm has a market cap of $377.65 million, a PE ratio of -3.45 and a beta of 0.61. The business’s 50-day moving average price is $2.05 and its two-hundred day moving average price is $1.82.

Insider Buying and Selling

In other news, insider Timothy Edward Lee sold 20,964 shares of the stock in a transaction dated Wednesday, February 18th. The shares were sold at an average price of $1.58, for a total transaction of $33,123.12. Following the completion of the transaction, the insider directly owned 117,717 shares in the company, valued at $185,992.86. This represents a 15.12% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, insider Julie Green sold 20,964 shares of the company’s stock in a transaction that occurred on Wednesday, February 18th. The stock was sold at an average price of $1.58, for a total value of $33,123.12. Following the sale, the insider owned 107,717 shares in the company, valued at approximately $170,192.86. This represents a 16.29% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold 227,172 shares of company stock valued at $354,534 over the last ninety days. Insiders own 25.40% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in the company. DRW Securities LLC bought a new position in shares of Invivyd in the 4th quarter valued at $27,000. State of Wyoming bought a new position in Invivyd during the fourth quarter worth $30,000. Schonfeld Strategic Advisors LLC acquired a new stake in shares of Invivyd in the 4th quarter valued at about $36,000. CIBC Asset Management Inc bought a new stake in shares of Invivyd during the fourth quarter valued at approximately $37,000. Finally, Fortress Private Ledger LLC acquired a new stake in shares of Invivyd in the 4th quarter worth about $62,000. 70.36% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

IVVD has been the subject of several research analyst reports. D. Boral Capital reiterated a “hold” rating on shares of Invivyd in a research report on Tuesday, November 25th. Zacks Research raised shares of Invivyd from a “strong sell” rating to a “hold” rating in a research note on Thursday, November 13th. BTIG Research reiterated a “buy” rating and issued a $10.00 price target on shares of Invivyd in a report on Thursday, February 26th. Finally, Weiss Ratings restated a “sell (e+)” rating on shares of Invivyd in a report on Monday, December 29th. Three analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Hold” and an average target price of $8.00.

About Invivyd

Invivyd, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering. Its pipeline includes PEMGRADA (pemivibart) injection, a half-life extended investigational monoclonal antibody (mAb) for the prevention of COVID-19 in adults and adolescents; VYD2311, an mAb candidate which is in preclinical studies for the prevention or treatment for COVID-19; and adintrvimab, that is in phase 3 clinical trials for the prevention or treatment of COVID-19.